계명대학교 의학도서관 Repository

Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor

Metadata Downloads
Author(s)
Seock-Ah ImSung-Bae KimMoon Hee LeeYoung-Hyuck ImKyung Hee LeeHong-Suk SongMyung-Ah LeeJunglim LeeNam-Su LeeHae Sun HamTae-You KimYeon Hee ParkKyung Eun LeeKee Won KimJae Hong SeoSoon Nam LeeYoung Seon HongYung-Jue BangWoo-Kun KimHee-Sook Park
Keimyung Author(s)
Song, Hong Suk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Oncology Reports
Issued Date
2005
Volume
14
Issue
2
Abstract
The anthracyclines and taxanes are considered to be the most active drugs in metastatic breast cancer (MBC). We conducted a multicenter phase II study to evaluate the efficacy and tolerability of the docetaxel plus epirubicin combination chemotherapy as first-line treatment in MBC and performed a prospective assessment of the predictive values of circulating HER2 extracellular domain (ECD) and vascular endothelial growth factor (VEGF). Docetaxel 75 mg/m2 and epirubicin 75 mg/m2 were given intravenously every 3 weeks. Prophylactic G-CSF was not used. Pretreatment serum HER2 ECD and VEGF levels were measured by enzyme immunoassay. Forty MBC patients were enrolled, and 39 patients were evaluable for toxicities and 38 for response. Complete response was observed in 3 (7.9%) patients, partial response in 20 (52.6%) (overall response rate 60.5%), stable disease in 11 (28.9%) and disease progression in 4 (10.5%). After a median follow-up of 22.5 months, the median duration of response was 28 weeks, median time to disease progression was 32 weeks, and median survival was 15.8 months. Two-hundred and fifteen cycles of treatment were administered (median, 6 cycles per patient). Grade 3 and 4 neutropenia were observed during 24 (11.2%) and 74 (35%) cycles respectively, and grade 3 or 4 febrile neutropenia in 24 (11.2%) cycles. Elevated circulating HER2 ECD levels were found to be associated with a shorter response duration (p<0.005) and shorter time to progression (p<0.005). However, elevated VEGF levels were not found to be correlated with response rate or survival. We concluded that the docetaxel and epirubicin combination is an effective first-line treatment in MBC patients and that elevated serum HER2 ECD levels, but not circulating VEGF levels, predict a poor outcome.
Keimyung Author(s)(Kor)
송홍석
Publisher
School of Medicine
Citation
Seock-Ah Im et al. (2005). Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncology Reports, 14(2), 481–487. doi: 10.3892/or.14.2.481
Type
Article
ISSN
1021-335X
Source
https://www.spandidos-publications.com/or/14/2/481
DOI
10.3892/or.14.2.481
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33599
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.